Ryan R Thompson1, Christina L Kong1, Travis C Porco1,2,3, Eric Kim1, Caleb D Ebert1, Nisha R Acharya1,2,3,4. 1. Francis I. Proctor Foundation, University of California, San Francisco, California, USA. 2. Department of Ophthalmology, University of California, San Francisco, California, USA. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA. 4. OptumLabs Visiting Fellow, Cambridge, Massachusetts, USA.
Abstract
BACKGROUND: The incidence of herpes zoster (HZ) has been increasing in recent decades. Although 2 vaccines for HZ are available, there have been few studies on the incidence rates of HZ and postherpetic neuralgia (PHN) since their introduction. This study examined the incidence rates of HZ and PHN from 1994 to 2018 in the United States to determine if they have continued to increase since introduction of the HZ vaccines. METHODS: A de-identified longitudinal administrative claims database, the OptumLabs Data Warehouse, was used to assess incidence rates among individuals continuously enrolled in the database for ≥365 days with no prior history of HZ or PHN. Unstandardized and standardized incidence rates were calculated by year, 10-year age groups, sex, and race/ethnicity. RESULTS: There were 610 766 individuals with HZ (median age, 56.3; interquartile range, 43.0-68.7 years; 59.8% women; 70.6% white). From 1994 to 2018, the incidence of HZ increased from 286.0 (95% confidence interval [CI], 259.1-312.8) to 579.6 (95% CI, 554.2-605.0) cases per 100 000 person-years, an annual increase of 3.1% (95% CI, 2.5-3.6%). Since 2007, annual HZ incidence rates have decreased in individuals ≤20 and >60 years old. The overall incidence rate of PHN was 57.5 (95% CI, 56.0-59.0) cases per 100 000 person-years. The proportion of individuals with HZ who developed PHN was higher from 2007 to 2018 than from 1994 to 2006. CONCLUSIONS: HZ incidence rates have continued to increase in age groups for which HZ vaccines are not currently recommended, warranting a review of current vaccine recommendations.
BACKGROUND: The incidence of herpes zoster (HZ) has been increasing in recent decades. Although 2 vaccines for HZ are available, there have been few studies on the incidence rates of HZ and postherpetic neuralgia (PHN) since their introduction. This study examined the incidence rates of HZ and PHN from 1994 to 2018 in the United States to determine if they have continued to increase since introduction of the HZ vaccines. METHODS: A de-identified longitudinal administrative claims database, the OptumLabs Data Warehouse, was used to assess incidence rates among individuals continuously enrolled in the database for ≥365 days with no prior history of HZ or PHN. Unstandardized and standardized incidence rates were calculated by year, 10-year age groups, sex, and race/ethnicity. RESULTS: There were 610 766 individuals with HZ (median age, 56.3; interquartile range, 43.0-68.7 years; 59.8% women; 70.6% white). From 1994 to 2018, the incidence of HZ increased from 286.0 (95% confidence interval [CI], 259.1-312.8) to 579.6 (95% CI, 554.2-605.0) cases per 100 000 person-years, an annual increase of 3.1% (95% CI, 2.5-3.6%). Since 2007, annual HZ incidence rates have decreased in individuals ≤20 and >60 years old. The overall incidence rate of PHN was 57.5 (95% CI, 56.0-59.0) cases per 100 000 person-years. The proportion of individuals with HZ who developed PHN was higher from 2007 to 2018 than from 1994 to 2006. CONCLUSIONS: HZ incidence rates have continued to increase in age groups for which HZ vaccines are not currently recommended, warranting a review of current vaccine recommendations.
Authors: Ralph P Insinga; Robbin F Itzler; James M Pellissier; Patricia Saddier; Alexander A Nikas Journal: J Gen Intern Med Date: 2005-08 Impact factor: 5.128
Authors: Aisha O Jumaan; Onchee Yu; Lisa A Jackson; Kari Bohlke; Karin Galil; Jane F Seward Journal: J Infect Dis Date: 2005-05-12 Impact factor: 5.226
Authors: Himal Lal; Anthony L Cunningham; Olivier Godeaux; Roman Chlibek; Javier Diez-Domingo; Shinn-Jang Hwang; Myron J Levin; Janet E McElhaney; Airi Poder; Joan Puig-Barberà; Timo Vesikari; Daisuke Watanabe; Lily Weckx; Toufik Zahaf; Thomas C Heineman Journal: N Engl J Med Date: 2015-04-28 Impact factor: 91.245
Authors: Sharon L Cadogan; Jennifer S Mindell; Judith Breuer; Andrew Hayward; Charlotte Warren-Gash Journal: BMC Infect Dis Date: 2022-06-01 Impact factor: 3.667
Authors: Yuwei Sun; Eric Kim; Christina L Kong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079
Authors: Yuwei Sun; Kaitlyn Jackson; Cyril A Dalmon; Brett L Shapiro; Sixiang Nie; Carmen Wong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya Journal: Vaccine Date: 2021-06-08 Impact factor: 4.169